Zero Candida Technologies Inc. · TSXV:ZCT
Zero Candida Technologies — Investor Presentation (March 2025)
9 slides from Zero Candida Technologies's investor presentation, March 2025
Slide 1: Zero Candida Technologies
TSXV: ZCT FSE: 9L2 OTCQB: ZCTFF
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements based on expectations, forecasts, and assumptions about future events or performance. These statements can be identified by terms such as “will,” “may,” “estimate,” “expect,” “plan,” “project,” “intend,” “anticipate,” o
Slide 3: ZCT Overview
ZCT OVERVIEW Revolutionizing Women’s Health Groundbreaking technological advancements in FemTech; industry expected to exceed $115 Billion in the next 4 years. Founded by a team of experienced healthcare experts and entrepreneurs. Fully patented in Africa, with applications filed in Europe, USA, and
Slide 4: Candidiasis
CANDIDIASIS POORLY RECCURENT FOR HHIGHEST AFFECTS 3 OUT OF 4 UNDERSTOOD AND HUNDREDS OF PREVALENCE SEEN WOMEN WORLDWIDE INCREASINGLY DRUG MILLIONS OF WOMEN IN WOMEN BETWEEN IN THEIR LIFETIME RESISTANT EACH YEAR 24 TO 34 YEARS OLD Vulvo-Vaginal Candidiasis (“VVC”) is a fungal *In Billion $ infection
Slide 5: Current Treatment
CURRENT TREATMENT Standard Therapy • Vaginal Ovules • Creams In many cases • Oral Drugs are ineffective... Therapeutic Failures Host Microbial Lack of Drug Susceptibilities Resistence Efficacy Alteration in the Reduction in the Low drug immune system intracellular level of drug bio-availability • Im
Slide 6: The Technology
THE TECHNOLOGY A non-drug blue light therapy in a SMART vaginal diagnostic device designed for the millions of women suffering from candidiasis. Offering precise and personalized treatment, with individualized light frequency targeting, to produce 99.999% fungal eradication in only 3 hours. Zero Can
Slide 7: ZC-01 Device
ZC-01 DEVICE Transparent Gel Matrix Image Sensor Temperature Sensor pH Sensor Discreet and Patient-Centric Design Novel Therapeutic Antimicrobial Blue Light Bleeding Sensor Wi-Fi Chip 7
Slide 8: Upcoming Milestones
UPCOMING MILESTONES OTC Listing & DTC Frankfurt Stock Eligibility Exchange Listing Q1 Q2 Attend Gynaecology/ Finalize Human Investor Conferences Prototype Finish pre-clinical Present results to FDA animal study for review Q3 Q4 Commence clinical Apply for 510(k) trials 8
Slide 9: Contact Details
TSXV: ZCT OTCQB: ZCTFF FSE: 9L2 zero-candida.com Contact Details: info@zero-candida.com +1 (647) 874 3767
Zero Candida Technologies — Investor Presentation (March 2025) on 6ix